STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa
It comes as the regional ministry of health revealed - without the data yet being public - waiting times had shot up again in December following poor results last June
Overall response rates were similar across subgroups of patients with nonsquamous non–small cell lung cancer for the combinations of dostarlimab-gxly plus chemotherapy and pembrolizumab plus chemotherapy, and responses numerically favored the dostarlimab-based combination in most subgroups, according to a subgroup analysis of the phase 2 PERLA trial.
/PRNewswire/ Proscia®, a leader in digital and computational pathology solutions, and University Hospital of Jaén have partnered to modernize the hospital s.
Spanish Researchers Begin Trialing Olive-Derived Treatment for Long Covid oliveoiltimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oliveoiltimes.com Daily Mail and Mail on Sunday newspapers.